Alto Neuroscience (ANRO) closed at $21.97 on October 23, 2026, down 1.0% from the previous close, on volume of 364,581 shares (30-day average 643,331).
Data as of October 23, 2026.
23-Oct-2026
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Business Wire (Wed, 9-Sep 8:03 AM ET)
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Business Wire (Thu, 27-Aug 4:05 PM ET)
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Business Wire (Wed, 12-Aug 4:03 PM ET)
Market Chameleon (Thu, 14-May 6:45 AM ET)
ANRO’s $50 Million Financing Signals Aggressive Push in Treatment-Resistant Depression Research
Market Chameleon (Mon, 20-Oct 6:29 AM ET)
Alto Neuroscience Secures $50 Million to Fast-Track Key Depression Drug: Here’s What Stands Out
Market Chameleon (Mon, 20-Oct 3:54 AM ET)
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.
As of October 23, 2026, ANRO stock price declined to $21.97 with 364,581 million shares trading.
ANRO has a beta of 2.20, meaning it tends to be more sensitive to market movements. ANRO has a correlation of 0.08 to the broad based SPY ETF.
ANRO has a market cap of $862.15 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ANRO has outperformed the market in the last year with a return of +96.5%, while the SPY ETF gained +14.3%. However, in the most recent history, ANRO shares have underperformed the stock market with its stock returning -18.2% in the last 3 month period and -9.8% for the last 2 week period, while SPY has returned +3.2% and -2.4%, respectively.
ANRO support price is $21.19 and resistance is $23.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.
